{'fraction_non_alphanumeric': 0.029411764705882353, 'fraction_numerical': 0.016544117647058824, 'mean_word_length': 5.775933609958506, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Basic fibroblast growth factor inhibits osteoclast‐like cell formation

Basic fibroblast growth factor (bFGF) inhibited osteoclast‐like cell formation in co‐cultures of mouse bone marrow cells either with the mouse stromal cell line, ST2, or with primary osteoblastic cells. Basic FGF significantly inhibited the osteoclast‐like cell formation, induced by 1α,25‐dihydroxyvitamin D3[1α, 25(OH)2D3] when the cytokine was added to the culture, at an intermediate stage, suggesting that bFGF inhibits the differentiation of the osteoclast progenitors. With regard to target cells, bFGF directly affected ST2; it increased [3H]thymidine uptake and decreased the number of alkaline phosphatase‐positive cells. In contrast, bFGF had no inhibitory effect on the colony formation of bone marrow cells induced by macrophage colony stimulating factor in methylcellulose culture. In addition, ST2 cells treated with bFGF produced similar amounts of colony forming activity to those without the cytokine. These findings indicated that the bFGF is not involved in the proliferation of progenitor cells even in the presence of ST2 cells. Furthermore, bFGF inhibited osteoclast‐like cell formation induced not only by 1α,25(OH)2D3, but also by prostaglandin E2 and by interleukin‐11. These results suggest that bFGF inhibits the common site of osteoclast‐like cell formation, as induced by different mechanisms. Our data also indicated that the target cells for bFGF in inhibiting osteoclast formation are not osteoclast progenitors but stromal cells such as ST2 and osteoblastic cells, which support osteoclast development. © 1996 Wiley‐Liss, Inc.